Novartis’ pelacarsen fails to meet primary endpoint in Lp(a)HORIZON trial
Phase 3negativepelacarsenNegative
AI Analysis
Summary
Novartis announced that pelacarsen failed to meet the primary endpoint in the Phase III Lp(a)HORIZON trial for patients with elevated Lp(a) and established cardiovascular disease. This represents a significant setback for the lipid-lowering therapeutic program.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Not Met
Outcome Details
Failed to meet primary endpoint
Importance:8/10
Sentiment:
-0.90
Phase 3 failurepelacarsenLp(a)cardiovascular diseaseprimary endpoint missed
Related Companies
Read the original article
Published by Clinical Trials Arena on September 7, 2026 8:59 AM